An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Asparlas

Chemical Namecalaspargase pegol-mknl
Dosage FormInjection (intravenous; 3,750 units/5 mL)
Drug ClassEnzymes
SystemBlood
CompanyServier Pharmaceuticals LLC.
Approval Year2018

Indication

  • Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Asparlas (Calaspargase Pegol-mknl) Prescribing Information 2018Servier Pharmaceuticals LLC., Boston, MA
Document TitleYearSource
A pilot study of intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase, IND# 100594) or intravenous Oncaspar® in the treatment of patients with high-risk acute lymphoblastic leukemia (ALL). 2020Children's Oncology Group
Randomized study of intravenous calaspargase pegol (SC-PEG Asparaginase) and intravenous Oncaspar in children and adolescents with acute lymphoblastic leukemia or lymphoblastic lymphoma. 2020Dana-Farber Cancer Institute
Document TitleYearSource
Pediatric acute lymphoblastic leukemia, version 2.2020. 2020NCCN Clinical Practice Guidelines in Oncology